Gadolinium meets medicinal chemistry: MRI contrast agent development

被引：64

作者：

Zhang, ZD ^{[1
]}

Nair, SA ^{[1
]}

McMurry, TJ ^{[1
]}

机构：

[1] EPIX Pharmaceut Inc, Cambridge, MA 02142 USA

来源：

CURRENT MEDICINAL CHEMISTRY | 2005年 / 12卷 / 07期

关键词：

MRI; contrast agents; gadolinium; extracellular contrast agents; liver contrast agents; vascular contrast agents (blood pool contrast agents); responsive or 'smart' agents;

D O I：

10.2174/0929867053507379

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Magnetic resonance imaging (MRI) contrast agents are utilized adjunctively to enhance the contrast between normal and abnormal structures on MRI scans. Along with the rapid evolution of the field has come a new appreciation for the medicinal chemistry of this unique class of metallopharmaceuticals. The efficacy of MRI agents is a complex function of chemical, biophysical, and pharmacological properties, which must be married in a package of exquisite safety. This report illustrates the wide range of medicinal chemistry relevant to existing agents that are either approved or in clinical development, as well as concepts, which may result in exciting new pharmaceuticals in the future.

引用

页码：751 / 778

页数：28

共 109 条

[21]

CARAVAN P, 2001, 222 ACS NAT M CHIC I

[22] Focal malignant hepatic lesions: MR imaging enhanced with gadolinium benzyloxypropionictetra-acetate (BOPTA) - Preliminary results of phase II clinical application [J].